News
FEops HEARTguideTM receives CE mark
The Avicenna Alliance Secretariat is proud to announce that one of its members, FEops, has received the ‘CE’ mark for its FEops HEARTguideTM. The CE marking proves that a product has been assessed by the relevant notified bodies and meets all the European requirements on safety, health and environmental protection enabling the manufacturer to sell his product in the European Economic Area.
Avicenna Alliance at the 2019 BMES Conference – Frontiers in medical devices
The Avicenna Alliance returned to the BMES Conference this year providing an opportunity to catch up with current members and to engage with potential new members.
Avicenna Alliance at Capitol Hill for meetings at the US Congress
The Avicenna Alliance returns from a contact programme to the US Senate and House of Representatives with resounding success and clear next steps for furthering in silico medicine through policy. The delegation, consisting of Avicenna Alliance members, 4 representatives of the US Food and Drug Administration (FDA) and 2 Observer Representatives of the European Commission met with the Office of Senator Ben Cardin and of Representative Dutch Ruppersberger.
VPH institute – Drives In Silico technology to the clinic
The VPH institute is an open community of scientists and clinicians focused on the development and uptake of computer modeling & simulation in healthcare. It is not just a scientific society as it involves a wide range of external stakeholders, such as industry and policy representatives, and federal agency employees that collaborate with the VPH Institute to advance the field of predictive medicine and make sure that in silico technology can make it to the clinic.
Avicenna Alliance returns to the BMES/FDA Conference and the US Congress
Following the resounding success of the Avicenna Alliance mission to the US in 2017, the Alliance is returning in 2019 to the BMES/FDA Frontiers in Medical Devices Conference and the US Congress during the week of the 18th March.
Resignation of FDA Commissioner Gottlieb – a note of Marco Viceconti
We have read this morning that Scott Gottlieb, US Food and Drug Administration Commissioner, will leave the job at the end of the month, for personal reasons. We cannot comment in general on his tenure, but with respect to the specific focus on eHealth and in silico methods we will miss him. Dr Gottlieb has been, since his appointment, a clear supporter of the modernisation of the regulatory process by means of innovative technologies in general, and in silico methods in particular.
